Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$27.12 USD

27.12
746,353

+0.53 (1.99%)

Updated Oct 10, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal

by Zacks Equity Research

Per the agreement with the European Commission, Valneva (VALN) has 30 days from May 13, 2022 to win a marketing authorization in the EU for its COVID vaccine or offer an acceptable remediation plan.

Bristol Myers (BMY) Phase III CheckMate -901 Study Disappoints

by Zacks Equity Research

Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.

Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold

by Zacks Equity Research

Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.

Here's Why You Should Hold STERIS (STE) Stock in Your Portfolio

by Zacks Equity Research

Investors are optimistic about STERIS (STE) due to its strong fiscal fourth-quarter results.

LabCorp (LH) Debuts At-home Collection Kit for Diabetes Testing

by Zacks Equity Research

LabCorp's (LH) at-home collection kit makes it effortless for consumers to understand their diabetes risk and health status using an innovative and approved collection device.

AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug

by Zacks Equity Research

AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene

Chimerix (CMRX) Plunges on Unfavorable Pipeline Updates

by Zacks Equity Research

The development of Chimerix's (CMRX) lead candidate, ONC201, gets delayed as the FDA states that data from the retrospective study is unlikely to support an approval. The company ends the DSTAT program.

CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

by Zacks Equity Research

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

Medtronic's (MDT) Onyx Frontier DES Receives FDA Approval

by Zacks Equity Research

Medtronic's (MDT) Onyx Frontier DES is utilized to treat patients with CAD.

    Here's Why You Should Retain Charles River (CRL) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.

      Will Repligen's (RGEN) COVID Woes Be Offset by Product Demand?

      by Zacks Equity Research

      The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.

      Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod

      by Zacks Equity Research

      Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.

      BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor

      by Zacks Equity Research

      BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.

      NEOGEN (NEOG) Introduces InfiniSEEK for Cattle Breeders

      by Zacks Equity Research

      NEOGEN's (NEOG) recent launch enables simultaneous low-pass whole genome sequencing and high-coverage genotyping at regions of interest.

        AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals

        by Zacks Equity Research

        AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.

        Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow

        by Zacks Equity Research

        Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.

        STERIS (STE) Q4 Earnings Surpass Estimates, Gross Margin Rises

        by Zacks Equity Research

        Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.

        Globus Medical (GMED) Q1 Earnings Miss Estimates, Margins Dip

        by Zacks Equity Research

        According to Globus Medical (GMED), its Q1 results reflect modest revenue growth against a difficult prior-year comparison, coupled with COVID-related revenue impacts in key countries.

        Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates

        by Zacks Equity Research

        Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.

        Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider

        by Zacks Equity Research

        Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023. BHVN also reports wider-than-expected Q1 loss.

        Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up

        by Zacks Equity Research

        Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.

        Here's Why You Should Hold on to Henry Schein (HSIC) Now

        by Zacks Equity Research

        Investors are optimistic about Henry Schein (HSIC) on favorable international Dental business trends and bullish guidance.

          National Vision (EYE) Tops Q1 Earnings Estimates, Cuts '22 View

          by Zacks Equity Research

          National Vision (EYE) reports better-than-expected earnings and an increase in store count for the first quarter.

          Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays

          by Zacks Equity Research

          Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.

          Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs

          by Zacks Equity Research

          Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.